IRadimed Rides 3870 Momentum Despite Near-Term Dip

Iradimed Corp ((IRMD)) has held its Q1 earnings call. Read on for the main highlights of the call.

IRadimed’s latest earnings call struck a notably upbeat tone, as management leaned on double‑digit revenue and profit gains, robust cash generation and a stronger‑than‑expected launch for its new 3870 MRI pump. While executives acknowledged near‑term revenue pressure from product transition and operational ramp‑up, they framed these as manageable bumps on an otherwise accelerating growth path.

Revenue Growth

IRadimed opened the year with clear top‑line momentum, reporting Q1 2026 revenue of $22.0 million, up 13% from $19.5 million in the prior‑year quarter. Management highlighted this growth as evidence of solid demand across its MRI‑compatible product portfolio, despite being in the early innings of transitioning to its next‑generation 3870 pump.

Improved Profitability

Profitability moved even faster than revenue, showcasing strong operating leverage in the model. Operating income climbed 33% year over year to $7.2 million, while GAAP net income rose 22% to $5.8 million, or $0.45 per diluted share, and non‑GAAP earnings improved 17% to $6.4 million, or $0.49 per share.

Strong Segment Performance

Growth was broad‑based but led by IV infusion pump systems, where revenue jumped 28% year over year to $7.7 million as the company worked down backlog. Patient monitoring posted a solid 9% gain to $7.1 million, while disposables were flat at $4.9 million and ferro‑magnetic detection systems contributed a modest $0.6 million, underscoring both strength and pockets of limited near‑term upside.

Healthy Margins and Cash Generation

Margins remained a standout, with gross profit of $16.8 million translating into a 77% gross margin, up from 76% a year ago and supporting the company’s earnings expansion. Cash generation was similarly strong, as operating cash flow nearly doubled to $8.3 million and non‑GAAP free cash flow reached $7.8 million, leaving cash and equivalents at $56.4 million and underpinning capital return and growth plans.

Very Promising 3870 Product Launch

The early rollout of the 3870 MRI IV pump was the star of the call, with initial orders delivering an average selling price uplift closer to 20% versus earlier expectations of 10% to 14%. Most early orders are quad four‑channel systems, which meaningfully increases revenue per order and installed channel count, and management said both order volume and deal sizes are running well ahead of internal projections.

Clear Runway and Financial Targets

Management underscored a long runway for growth and reaffirmed full‑year 2026 targets of $91 million to $96 million in revenue and GAAP diluted EPS of $1.90 to $2.05, alongside non‑GAAP EPS of $2.06 to $2.21. The board also backed confidence with a quarterly dividend of $0.20 per share, as executives outlined a path toward a domestic pump run‑rate above 2,000 channels and a longer‑term company revenue run‑rate north of $100 million as 3870 adoption and ancillary revenue build.

Near‑Term Revenue Transition Pressure

Despite strong Q1 numbers, the company guided to a sequential dip in Q2 revenue to $20 million to $21 million, below the $22.0 million just posted. Management framed this softness as a temporary transition issue, as waning sales of the older 3860 pumps offset early 3870 shipments, meaning second‑quarter results will not yet fully reflect the strength of current ordering activity.

Constrained Manufacturing Ramp

Execution, not demand, is the near‑term bottleneck for the 3870, with management planning to ship only about 130 to 135 units in Q2 even though sales would prefer more than 200. Leadership said they are intentionally ramping production cautiously to stabilize the supply chain and deepen manufacturing know‑how, a prudent approach that may delay some revenue but aims to reduce operational risk.

Concentration and Small Adjacencies

The call also highlighted some structural limitations, including a continued reliance on the U.S. market, which accounted for 82% of revenue and leaves the company exposed to domestic demand trends. Smaller product lines such as ferro‑magnetic detection, at $0.6 million in sales, and flat disposables at $4.9 million remain early‑stage contributors, offering long‑term optionality but little immediate growth ballast.

Temporary Expense and Tax Headwinds

Operating expenses ticked higher, particularly in R&D, as IRadimed stopped capitalizing software costs for the 3870 and invested in next‑generation monitoring products. The effective tax rate was also elevated at roughly 25% due to timing effects tied to equity awards, but management expects the rate to ease later in the year, suggesting a partial headwind that should fade over coming quarters.

Early‑Stage Execution Risk on 3870

Management’s optimism around higher 3870 pricing and strong quad‑system demand came with a note of caution about drawing long‑term conclusions too soon. The ultimate financial impact will depend on sustaining the replacement cadence, maintaining a rich mix of four‑channel systems and executing on a smooth scale‑up in manufacturing and supply, all of which introduce execution risk even against a large replacement opportunity.

Guidance and Outlook

For Q2, IRadimed forecast revenue of $20.0 million to $21.0 million, GAAP diluted EPS of $0.40 to $0.44 and non‑GAAP EPS of $0.44 to $0.48, while reaffirming full‑year 2026 revenue guidance of $91 million to $96 million and the same EPS ranges discussed on the call. Management pointed to a sizable pool of roughly 6,400 aging domestic 3860 channels and historical replacement rates as the basis for targeting more than 2,000 annual 3870 channels and an eventual pump revenue run‑rate near $50 million within a broader $100 million‑plus company profile.

In closing, IRadimed’s earnings call painted a picture of a company in the sweet spot of a product transition, absorbing modest short‑term bumps as it leans into a higher‑margin, higher‑ASP growth driver. For investors, the story now turns on execution: if management can scale the 3870 smoothly and tap its sizable replacement market, the current momentum suggests meaningful upside to the company’s long‑term earnings power.